Newbury Pharmaceuticals year-end report September 2021 – August 2022

“Looking into the next year, we continue to focus on three strategic levers: Maximize value of the commercial launches and business development opportunities while enabling the organization to execute for results”
 –Lars Minor CEO

Quarter 4, June 2022 – August 2022
· Net revenue was 4 570 (2 097) tkr.
· EBITDA was -3 626 (-1 822) tkr.
· Operating cash flow was -4 987 (-860) tkr.

Year-end period, September 2021 – August 2022
· Net revenue was 5 516 (2 829) tkr.
· EBITDA was -13 661 (-5 013) tkr.
· Operating cash flow was -15 001 (-4 066) tkr.
· Cash position in the end of period was 33 334 (13 145) tkr.
· Licensed products in the end of period were 30 (17).
· Products with marketing authorization in the end of the period were 4 (0).

Significant events during the quarter
· Strengthening the portfolio with Teriparatide injection in pre-filled pen.
· “Icatibant Newbury” win the Swedish market tender for June and July.
· Expands the team with appointment of Mrs. Andrea Karnitschky as Senior Director and Head of Business Development.

Significant events after the end of the quarter
· Winning a tender for Sunitinib in Norway and winning the period of the month (Nov) for Icatibant in Sweden combined worth app 500 tkr.

A word from the CEO
Following the launch of Icatibant Newbury in May, we also achieved to win the period of the month for Icatibant in Sweden for the month of both June and July. The launch of Icatibant Newbury has paved the way for future launches. Next is the launch of Lenalidomid Newbury, – the first of 11 planned launches within oncology. This will be followed by Sunitinib and consequently increase the number of launched products to three in the near future.

Growing the pipeline
During the Quarter we announced the addition of Teriparatide pre-filled injection pen which is a synthetic follow-on version for the recombinant (biological) teriparatide (Forsteo®) indicated for treatment of osteoporosis and it has been developed by utilizing fast-developing synthetic technologies. The addition of this non-biological complex drug is a terrific supplement to the existing portfolio and our strategic focus on specialty medicine. In addition, we have secured a new strategic partnership which can be an advantage when sourcing future products.

In total we now have 30 products licensed for commercialization over the coming years.

Strengthening the organization
To strengthen our reach and capabilities, we have as of 1st August hired a Head of Business Development with a solid track record from the industry. Besides nurturing our existing partnerships, we aim to identify new partnerships based on either licensing models or distribution rights. Both models will work and we remain diligent in pursuing new partnerships and building our pipeline of products.

Looking ahead
Looking into the next year, we continue to focus on three strategic levers:
· Maximize value of the commercial launches
· Maximize business development opportunities
· Enable the organization to execute for results

The regulatory path is constantly evolving, and we have already achieved national approval of four products, and we have 10 other products in regulatory procedures that are expected to be completed during 2023.

In line with the growth of the portfolio and the commercial launches, we expect to grow the organization. But we remain focused on maintaining our entrepreneurial spirit to remain agile and fit for the future.

The above demonstrate the focus on scaling the company for future launches and identifying product opportunities as well as ongoing regulatory filings of our portfolio which by now consist of 30 products planned for launch in the years ahead.

The report is publised on Newbury Pharmaceuticals website:
https://www.newburypharma.com/investors/financial-information/